Tri'L Biotech Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 21 Year, 1 Month
- Last Filing with ROC 31 Mar 2020
- Revenue Growth %
- Profit Growth 37.13%
- Ebitda -35.01%
- Net Worth -20.51%
- Total Assets 1296.67%
About Tri'L Biotech Pharmaceuticals
Tri'l Biotech Pharmaceuticals Private Limited (TBPPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 January 2004 and has a history of 21 years and one month. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rajindar Patha, Vanaja Patha, and Krishna Patha serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24239TG2004PTC042392
- Company No.
042392
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Jan 2004
- Date of AGM
28 Sep 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Tri'L Biotech Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajindar Patha  | Director | 08-Jan-2004 | Current |
| Vanaja Patha | Director | 30-Jun-2011 | Current |
| Krishna Patha | Director | 01-Feb-2014 | Current |
Financial Performance of Tri'L Biotech Pharmaceuticals.
Tri'L Biotech Pharmaceuticals Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 37.13% increase in profit. The company's net worth observed a substantial decline by a decrease of 20.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Tri'L Biotech Pharmaceuticals?
Unlock access to Tri'L Biotech Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Tri'L Biotech Pharmaceuticals?
Unlock and access historical data on people associated with Tri'L Biotech Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tri'L Biotech Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tri'L Biotech Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
